HER2 amplification / overexpression (HER2+ mCRC)
Gene: ERBB2 · Type: amplification
Indications: Colorectal cancer
Linked CIViC Profile: ERBB2 AMPLIFICATION
Evidence Level Distribution
Level A: 4Level B: 43Level C: 5Level D: 13
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab | 5 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab | 5 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Docetaxel,Trastuzumab,Pertuzumab | 5 |
| A | Predictive | Supports | Sensitivity/Response | Breast Cancer | Margetuximab | 5 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Lapatinib,Trastuzumab | 4 |
| B | Predictive | Does Not Support | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Lapatinib,Trastuzumab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab,Lapatinib | 4 |
| B | Predictive | Does Not Support | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Afatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Gastric Adenocarcinoma | Trastuzumab | 4 |
| C | Predictive | Supports | Sensitivity/Response | Lung Small Cell Carcinoma | Trastuzumab,Irinotecan | 4 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Trastuzumab Emtansine | 4 |
| B | Prognostic | Supports | Poor Outcome | Endometrial Serous Adenocarcinoma | 4 | |
| C | Predictive | Supports | Sensitivity/Response | Endometrial Serous Adenocarcinoma | Trastuzumab | 4 |
| A | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab,Neratinib | 4 |
| A | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Capecitabine,Lapatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab,Capecitabine | 4 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab Emtansine | 4 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab Emtansine | 4 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab,Docetaxel,Pertuzumab | 4 |